PROTAC K-Ras Degrader-3, identified by the CAS number 3043670-68-1, is a small molecule designed as a targeted protein degradation agent, specifically aimed at the K-Ras protein, which is often implicated in various cancers. This compound belongs to a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which function by harnessing the cell's ubiquitin-proteasome system to selectively degrade target proteins. The structure of PROTAC K-Ras Degrader-3 typically includes a ligand that binds to K-Ras and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of K-Ras. This mechanism allows for the reduction of K-Ras levels in cells, potentially leading to therapeutic effects in K-Ras-driven malignancies. The compound is characterized by its specificity, efficacy, and ability to overcome some of the limitations associated with traditional small molecule inhibitors, making it a promising candidate in cancer research and treatment strategies. Further studies are essential to fully understand its pharmacokinetics, bioavailability, and overall therapeutic potential.

PROTAC K-Ras Degrader-3

3043670-68-1: PROTAC K-Ras Degrader-3, identified by the CAS number 3043670-68-1, is a small molecule designed as a targeted protein degradation agent, specifically aimed at the K-Ras protein, which is often implicated in various cancers. This compound belongs to a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which function by harnessing the cell's ubiquitin-proteasome system to selectively degrade target proteins. The structure of PROTAC K-Ras Degrader-3 typically includes a ligand that binds to K-Ras and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of K-Ras. This mechanism allows for the reduction of K-Ras levels in cells, potentially leading to therapeutic effects in K-Ras-driven malignancies. The compound is characterized by its specificity, efficacy, and ability to overcome some of the limitations associated with traditional small molecule inhibitors, making it a promising candidate in cancer research and treatment strategies. Further studies are essential to fully understand its pharmacokinetics, bioavailability, and overall therapeutic potential.

<p>PROTAC K-Ras Degrader-3  is a PROTAC degrader targeting K-Ras, exhibiting a DC50 value of ≤ 1 nM against SW620 KRAS G12D and a GI50 value of ≤ 10 nM in inhibiting the growth of SW620 3D cells. It is used in cancer research.</p>

CAS 3043670-68-1

PROTAC K-Ras Degrader-3

PROTAC K-Ras Degrader-3

Ref: TM-T200521